Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma

Publikation: Bidrag til tidsskriftReviewfagfællebedømt

Standard

Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma. / Nielsen, Lene Kongsgaard; Abildgaard, Niels; Jarden, Mary; Klausen, Tobias Wirenfeld.

I: British Journal of Haematology, Bind 185, Nr. 1, 2019, s. 11-24.

Publikation: Bidrag til tidsskriftReviewfagfællebedømt

Harvard

Nielsen, LK, Abildgaard, N, Jarden, M & Klausen, TW 2019, 'Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma', British Journal of Haematology, bind 185, nr. 1, s. 11-24. https://doi.org/10.1111/bjh.15759

APA

Nielsen, L. K., Abildgaard, N., Jarden, M., & Klausen, T. W. (2019). Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma. British Journal of Haematology, 185(1), 11-24. https://doi.org/10.1111/bjh.15759

Vancouver

Nielsen LK, Abildgaard N, Jarden M, Klausen TW. Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma. British Journal of Haematology. 2019;185(1):11-24. https://doi.org/10.1111/bjh.15759

Author

Nielsen, Lene Kongsgaard ; Abildgaard, Niels ; Jarden, Mary ; Klausen, Tobias Wirenfeld. / Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma. I: British Journal of Haematology. 2019 ; Bind 185, Nr. 1. s. 11-24.

Bibtex

@article{ebf1929e6f004099b4db33d70b59ce52,
title = "Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma",
abstract = "Multiple myeloma (MM) is an incurable but treatment-sensitive cancer. For most patients, this means treatment with multiple lines of anti-myeloma therapy and a life with disease- and treatment-related symptoms and complications. Health-related quality of life (HRQoL) issues play an important role in treatment decision-making. Methodological challenges in longitudinal HRQoL measurements and analyses have been identified, including non-responses (NR) to scheduled questionnaires. Publications were identified for inclusion in a systematic review of longitudinal HRQoL studies in MM, focussing on methodological aspects of HRQoL measurement and analysis. Diversity in timing of HRQoL data collection and applied statistical methods were noted. We observed a high rate of NR, but the impact of NR was investigated in only 8/23 studies. Thus, evidence-based knowledge of HRQoL in patients with MM is compromised. To improve quality of HRQoL results and their implementation in daily practice, future studies should follow established guidelines.",
keywords = "health-related quality of life, missing data, multiple myeloma, review, statistical analysis",
author = "Nielsen, {Lene Kongsgaard} and Niels Abildgaard and Mary Jarden and Klausen, {Tobias Wirenfeld}",
year = "2019",
doi = "10.1111/bjh.15759",
language = "English",
volume = "185",
pages = "11--24",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma

AU - Nielsen, Lene Kongsgaard

AU - Abildgaard, Niels

AU - Jarden, Mary

AU - Klausen, Tobias Wirenfeld

PY - 2019

Y1 - 2019

N2 - Multiple myeloma (MM) is an incurable but treatment-sensitive cancer. For most patients, this means treatment with multiple lines of anti-myeloma therapy and a life with disease- and treatment-related symptoms and complications. Health-related quality of life (HRQoL) issues play an important role in treatment decision-making. Methodological challenges in longitudinal HRQoL measurements and analyses have been identified, including non-responses (NR) to scheduled questionnaires. Publications were identified for inclusion in a systematic review of longitudinal HRQoL studies in MM, focussing on methodological aspects of HRQoL measurement and analysis. Diversity in timing of HRQoL data collection and applied statistical methods were noted. We observed a high rate of NR, but the impact of NR was investigated in only 8/23 studies. Thus, evidence-based knowledge of HRQoL in patients with MM is compromised. To improve quality of HRQoL results and their implementation in daily practice, future studies should follow established guidelines.

AB - Multiple myeloma (MM) is an incurable but treatment-sensitive cancer. For most patients, this means treatment with multiple lines of anti-myeloma therapy and a life with disease- and treatment-related symptoms and complications. Health-related quality of life (HRQoL) issues play an important role in treatment decision-making. Methodological challenges in longitudinal HRQoL measurements and analyses have been identified, including non-responses (NR) to scheduled questionnaires. Publications were identified for inclusion in a systematic review of longitudinal HRQoL studies in MM, focussing on methodological aspects of HRQoL measurement and analysis. Diversity in timing of HRQoL data collection and applied statistical methods were noted. We observed a high rate of NR, but the impact of NR was investigated in only 8/23 studies. Thus, evidence-based knowledge of HRQoL in patients with MM is compromised. To improve quality of HRQoL results and their implementation in daily practice, future studies should follow established guidelines.

KW - health-related quality of life

KW - missing data

KW - multiple myeloma

KW - review

KW - statistical analysis

U2 - 10.1111/bjh.15759

DO - 10.1111/bjh.15759

M3 - Review

C2 - 30656677

AN - SCOPUS:85060210120

VL - 185

SP - 11

EP - 24

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -

ID: 241430828